Author: Network for Excellence in Health Innovation
Year of Publication: 2023
Abstract
A new era has begun with recent 2023 FDA approval of Leqembi, and the expected approval of donanemab, new drug therapies that remove a brain protein (amyloid-beta proteins accumulating as
plaques) implicated in Alzheimer’s disease. The new therapies are disease-modifying therapies. They are likely to be more effective the earlier they are administered in the progression of a patient’s disease. Thus, it will be critical for patients, caregivers, and clinicians to:
• Initiate early screening for dementia
• Verify that patients have Alzheimer’s disease and not other forms of dementia
• Detect the presence and the progression of amyloid plaques among patients with Alzheimer’s who are eligible for anti-amyloid therapies